Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability

Human Vaccines

Volumn 7, Issue 4, 2011, Pages

  Tan, Paul ThiamJoo ^a   Khan, Asif M ^a,b   August, J Thomas ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Altered peptide ligands; High conservation; Immunodominance; Immunoinformatics; Pan influenza; Pandemic H1N1; T cell epitopes based vaccine

Indexed keywords

CD8 ANTIGEN; EPITOPE; HEMAGGLUTININ; HLA ANTIGEN CLASS 2; INFLUENZA VACCINE; MATRIX PROTEIN; MATRIX PROTEIN 1; NUCLEOPROTEIN; PROTEIN PA; PROTEIN PB1; PROTEIN PB2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; GENETIC VARIABILITY; HELPER CELL; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N2; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS STRAIN; GENETICS; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A; T LYMPHOCYTE;

CONSERVED SEQUENCE; EPITOPES, T-LYMPHOCYTE; GENETIC VARIATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; T-LYMPHOCYTES;

EID: 79955042531     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.4.13845     Document Type: Review

References (81)

1. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009; 333:43-82.
2. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61:94-9.
3. Jin H, Zhou H, Liu H, Chan W, Adhikary L, Mahmood K, et al. Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift from A/Panama/2007/99. Virology 2005; 336:113-9.
4. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V, et al. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One 2007; 2:1190.
5. Shastri N, Schwab S, Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol 2002; 20:463-93. (Pubitemid 34293432)
6. Bjorkman PJ, Parham P. Structure, function and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990; 59:253-88.
7. Esser MT, Marchese RD, Kierstead LS, Tussey LG, Wang F, Chirmule N, et al. Memory T cells and vaccines. Vaccine 2003; 21:419-30. (Pubitemid 36096849)
8. Zinkernagel RM, Hengartner H. On immunity against infections and vaccines: credo 2004. Scand J Immunol 2004; 60:9-13. (Pubitemid 38943046)
9. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124:849-63. (Pubitemid 43261457)
10. Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, Kobasa D, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007; 25:6845-51. (Pubitemid 47398928)
11. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 2001; 19:3681-91. (Pubitemid 32522766)
12. Matsui M, Kohyama S, Suda T, Yokoyama S, Mori M, Kobayashi A, et al. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem Biophys Res Commun 2010; 391:1494-9.
13. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005; 23:5404-10. (Pubitemid 41579312)
14. + T cell response in mice homozygous for disruption of the H-2lAb gene. J Immunol 1995; 155:2955-9.
15. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 2006; 177:2888-98. (Pubitemid 44277804)
16. + T cells. J Exp Med 2009; 206:69-78.
17. Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med 1986; 164:1114-28. (Pubitemid 16031610)
18. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 2002; 76:12388-93. (Pubitemid 35304341)
19. + T cells: when, where and how. Annu Rev Immunol 2006; 24:519-40.
20. Schepers K, Arens R, Schumacher TN. Dissection of cytotoxic and helper T cell responses. Cell Mol Life Sci 2005; 62:2695-710. (Pubitemid 41779941)
21. Brown DM, Roman E, Swain SL. CD4 T cell responses to influenza infection. Semin Immunol 2004; 16:171-7. (Pubitemid 38569897)
22. Strutt TM, McKinstry KK, Swain SL. Functionally diverse subsets in CD4 T cell responses against influenza. J Clin Immunol 2009; 29:145-50.
23. Brown LE, Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009; 87:300-8.
24. Francis T. Influenza: The newe acquayantance. Ann Intern Med 1953; 39:203-21.
25. Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin responses to influenza viruses. J Immunol 2009; 183:3294-301.
26. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394:482-5. (Pubitemid 28373959)
27. Kundu SK, Dupuis M, Sette A, Celis E, Dorner F, Eibl M, et al. Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. AIDS Res Hum Retroviruses 1998; 14:1669-78. (Pubitemid 28563858)
28. Yellen-Shaw AJ, Wherry EJ, Dubois GC, Eisenlohr LC. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol 1997; 158:3227-34. (Pubitemid 127484038)
29. Sant'Angelo DB, Robinson E, Janeway CA Jr, Denzin LK. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur J Immunol 2002; 32:2510-20.
30. Beekman NJ, van Veelen PA, van Hall T, Neisig A, Sijts A, Camps M, et al. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J Immunol 2000; 164:1898-905. (Pubitemid 30108744)
31. Maverakis E, Beech JT, Schneider S, Sercarz EE. Presentation of a determinant by MHC class II can be prevented through competitive capture by a flanking determinant on a multideterminant peptide. J Autoimmun 2008; 31:59-65.
32. Theodossis A, Guillonneau C, Welland A, Ely LK, Clements CS, Williamson NA, et al. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition. Proc Natl Acad Sci USA 2010; 107:5534-9.
33. Anderson MW, Gorski J. Cutting edge: TCR contacts as anchors: effects on affinity and HLA-DM stability. J Immunol 2003; 171:5683-7. (Pubitemid 37467182)
34. James EA, Moustakas AK, Bui J, Nouv R, Papadopoulos GK, Kwok WW. The binding of antigenic peptides to HLA-DR is influenced by interactions between pocket 6 and pocket 9. J Immunol 2009; 183:3249-58.
35. Voeten JT, Bestebroer TM, Nieuwkoop NJ, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol 2000; 74:6800-7. (Pubitemid 30470663)
36. Rimmelzwaan GF, Boon AC, Voeten JT, Berkhoff EG, Fouchier RA, Osterhaus AD. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 2004; 103:97-100. (Pubitemid 38649067)
37. Berkhoff EG, Geelhoed-Mieras MM, Verschuren EJ, van Baalen CA, Gruters RA, Fouchier RA, et al. The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro. Clin Exp Immunol 2007; 148:296-306. (Pubitemid 46587587)
38. Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009; 27:6363-5.
39. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14:1-27. (Pubitemid 26130175)
40. Hlavac F, Choppin J, Guillet JG. Self-peptide ligands affect T cell recognition of the homologous influenza A matrix virus peptide M.58-66: modification of the HLA-A2.1/peptide complex structure and T cell antagonism. Hum Immunol 1997; 54:48-53. (Pubitemid 27216985)
41. Li X, Li R, Li Z. Influenza virus haemagglutinin-derived peptides inhibit T-cell activation induced by HLA-DR4/1 specific peptides in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:148-54. (Pubitemid 43826863)
42. Boon AC, de Mutsert G, Graus YM, Fouchier RA, Sintnicolaas K, Osterhaus AD, et al. Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol 2002; 76:2567-72. (Pubitemid 34150727)
43. Tsitoura DC, Holter W, Cerwenka A, Gelder CM, Lamb JR. Induction of anergy in human T helper 0 cells by stimulation with altered T cell antigen receptor ligands. J Immunol 1996; 156:2801-8. (Pubitemid 126660627)
44. Mirshahidi S, Ferris LC, Sadegh-Nasseri S. The magnitude of TCR engagement is a critical predictor of T cell anergy or activation. J Immunol 2004; 172:5346-55. (Pubitemid 38542033)
45. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, et al. The influenza virus resource at the National Center for Biotechnology Information. J Virol 2008; 82:596-601.
46. Berkhoff EG, de Wit E, Geelhoed-Mieras MM, Boon AC, Symons J, Fouchier RA, et al. Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. Vaccine 2006; 24:6594-6. (Pubitemid 46107162)
47. Wild J, Bojak A, Deml L, Wagner R. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model. Vaccine 2004; 22:1732-43. (Pubitemid 38447222)
48. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008; 181:4168-76.
49. Tan PT, Heiny AT, Miotto O, Salmon J, Marques ET, Lemonnier F, et al. Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLoS One 2010; 5:8754.
50. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38:854-62.
51. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009; 106:20365-70.
52. + T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 2010; 28:664-72.
53. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 2008; 82:12241-51.
54. Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, et al. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol 2010; 91:919-30.
55. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 2007; 8:424.
56. Doytchinova IA, Flower DR. In silico identification of supertypes for class II MHCs. J Immunol 2005; 174:7085-95.
57. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1.
58. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201-12. (Pubitemid 30099525)
59. Alexander J, Bilsel P, del Guercio MF, Marinkovic-Petrovic A, Southwood S, Stewart S, et al. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Hum Immunol 2010; 71:468-74.
60. th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol 2010; 160:15-21.
61. Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barre syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS One 2007; 2:344.
62. Toplak N, Avcin T. Influenza and autoimmunity. Ann NY Acad Sci 2009; 1173:619-26.
63. Louzoun Y, Vider T, Weigert M. T-cell epitope repertoire as predicted from human and viral genomes. Mol Immunol 2006; 43:559-69. (Pubitemid 41786961)
64. Burroughs NJ, de Boer RJ, Kesmir C. Discriminating self from nonself with short peptides from large proteomes. Immunogenetics 2004; 56:311-20.
65. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993; 11:729-66. (Pubitemid 23115022)
66. + T-cell responses to influenza virus. J Virol 2002; 76:10332-7.
67. Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000; 12:83-93. (Pubitemid 30069217)
68. + T-lymphocyte epitope immunodominance hierarchies. J Virol 2006; 80:11991-7.
69. + T cell responses. Immunity 2006; 25:533-43.
70. Sant AJ, Chaves FA, Jenks SA, Richards KA, Menges P, Weaver JM, et al. The relationship between immunodominance, DM editing and the kinetic stability of MHC class II: peptide complexes. Immunol Rev 2005; 207:261-78.
71. + T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities. Int Immunol 1998; 10:211-22.
72. Biswas SK, Nayak DP. Influenza virus polymerase basic protein 1 interacts with influenza virus polymerase basic protein 2 at multiple sites. J Virol 1996; 70:6716-22. (Pubitemid 26307378)
73. Poole E, Elton D, Medcalf L, Digard P. Functional domains of the influenza A virus PB2 protein: identification of NP- and PB1-binding sites. Virology 2004; 321:120-33. (Pubitemid 38368109)
74. Biswas SK, Boutz PL, Nayak DP. Influenza virus nucleoprotein interacts with influenza virus polymerase proteins. J Virol 1998; 72:5493-501. (Pubitemid 28283331)
75. Perez DR, Donis RO. A 48-amino-acid region of influenza A virus PB1 protein is sufficient for complex formation with PA. J Virol 1995; 69:6932-9.
76. Gonzalez S, Zurcher T, Ortin J. Identification of two separate domains in the influenza virus PB1 protein involved in the interaction with the PB2 and PA subunits: a model for the viral RNA polymerase structure. Nucleic Acids Res 1996; 24:4456-63. (Pubitemid 26388631)
77. Gonzalez S, Ortin J. Distinct regions of influenza virus PB1 polymerase subunit recognize vRNA and cRNA templates. EMBO J 1999; 18:3767-75. (Pubitemid 29308855)
78. Dias A, Bouvier D, Crepin T, McCarthy AA, Hart DJ, Baudin F, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009; 458:914-8.
79. Hara K, Schmidt FI, Crow M, Brownlee GG. Amino acid residues in the N-terminal region of the PA subunit of influenza A virus RNA polymerase play a critical role in protein stability, endonuclease activity, cap binding and virion RNA promoter binding. J Virol 2006; 80:7789-98. (Pubitemid 44182280)
80. Albo C, Valencia A, Portela A. Identification of an RNA binding region within the N-terminal third of the influenza A virus nucleoprotein. J Virol 1995; 69:3799-806.
81. Baudin F, Petit I, Weissenhorn W, Ruigrok RW. In vitro dissection of the membrane and RNP binding activities of influenza virus M1 protein. Virology 2001; 281:102-8.